Phase III ASP2138 with chemotherapy and pembrolizumab in CLDN18.2-positive HER2-negative advanced gastric or GEJ cancer
Sponsor: Astellas Pharma Global Development Inc.
Phase: 3
Disease: Gastric adenocarcinoma, Gastroesophageal junction adenocarcinoma
EU trial number: 2025-524557-14-00
Population: Adults with previously untreated unresectable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma, HER2-negative and CLDN18.2-positive by central testing, irrespective of PD-L1 expression.
Register Investigator Interest
Interested in offering this trial to suitable patients?